Last reviewed · How we verify
Placebo matched to prednisone
A placebo formulation designed to match the appearance and administration route of prednisone for use as a control in clinical trials.
A placebo formulation designed to match the appearance and administration route of prednisone for use as a control in clinical trials. Used for Clinical trial control comparator (not a therapeutic indication).
At a glance
| Generic name | Placebo matched to prednisone |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
This is not an active pharmaceutical agent but rather an inert control comparator used in randomized controlled trials to evaluate the efficacy of prednisone. Placebo-matched formulations are manufactured to be indistinguishable from the active drug in appearance, taste, and packaging to maintain blinding in clinical studies.
Approved indications
- Clinical trial control comparator (not a therapeutic indication)
Common side effects
Key clinical trials
- Prednisone in Adults With an Immune-Mediated Subtype of Autism Spectrum Disorder (EARLY_PHASE1)
- Study of LFD-200 in Healthy Adults and Adults With Moderate to Severe Rheumatoid Arthritis (PHASE1)
- An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC) (PHASE3)
- A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer (PHASE3)
- A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (PHASE3)
- A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) (PHASE2)
- A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies (PHASE2)
- Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo matched to prednisone CI brief — competitive landscape report
- Placebo matched to prednisone updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI